About CJC-1295 + Ipamorelin
CJC-1295 (no DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH) — specifically a modified GRF(1-29) fragment with amino acid substitutions that improve resistance to enzymatic degradation. It binds the GHRH receptor on pituitary somatotrophs and stimulates a natural, pulsatile release of growth hormone, mirroring the body's own signaling pattern rather than delivering exogenous GH directly.
Ipamorelin is a pentapeptide growth hormone secretagogue belonging to the GHRP (growth hormone-releasing peptide) class. It acts as a selective agonist at the ghrelin receptor (GHS-R), triggering GH release through a separate pathway from CJC-1295. What sets Ipamorelin apart from older-generation GHRPs is its selectivity — research indicates it produces minimal to no increase in cortisol, ACTH, or prolactin. Because CJC-1295 and Ipamorelin act on two distinct receptor systems that converge on GH release, the combination is studied for producing a larger, synergistic GH pulse than either compound used alone.
Research Applications
CJC-1295 + Ipamorelin is used in research investigating growth hormone secretion dynamics, body composition, lean mass, recovery, and sleep architecture. Because the combination targets two separate GH-release pathways, it is also of interest for studies comparing additive vs. synergistic GH secretagogue effects, and for evaluating downstream IGF-1 signaling.